Kenneth Hoberman
2014
In 2014, Kenneth Hoberman earned a total compensation of $1.8M as Chief Operating Officer at Stemline Therapeutics, a 112% increase compared to previous year.
Compensation breakdown
| Bonus | $200,000 |
|---|---|
| Non-Equity Incentive Plan | $40,000 |
| Option Awards | $759,820 |
| Salary | $400,000 |
| Stock Awards | $375,374 |
| Total | $1,775,194 |
Hoberman received $759.8K in option awards, accounting for 43% of the total pay in 2014.
Hoberman also received $200K in bonus, $40K in non-equity incentive plan, $400K in salary and $375.4K in stock awards.
Rankings
In 2014, Kenneth Hoberman's compensation ranked 5,014th out of 13,032 executives tracked by ExecPay. In other words, Hoberman earned more than 61.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,014 out of 13,032 | 62nd |
Division Manufacturing | 1,788 out of 4,966 | 64th |
Major group Chemicals And Allied Products | 591 out of 1,686 | 65th |
Industry group Drugs | 451 out of 1,365 | 67th |
Industry Pharmaceutical Preparations | 360 out of 1,043 | 66th |
Source: SEC filing on May 1, 2017.
Hoberman's colleagues
We found three more compensation records of executives who worked with Kenneth Hoberman at Stemline Therapeutics in 2014.